Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours

Histopathology

Volumn 68, Issue 7, 2016, Pages 977-987

  Strickland, Sarah ^a,b   Parra Herran, Carlos ^c,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Appendiceal adenocarcinoma; Low grade appendiceal mucinous neoplasm; Ovarian mucinous adenocarcinoma; Ovarian mucinous borderline tumour; SATB2

Indexed keywords

AT RICH SEQUENCE-BINDING PROTEIN 2; BETA CATENIN; BINDING PROTEIN; CYTOKERATIN; ESTROGEN RECEPTOR; MUCIN 1; MUCIN 2; MUCIN 5AC; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; CDX2 PROTEIN, HUMAN; CYTOKERATIN 20; KRT20 PROTEIN, HUMAN; MATRIX ATTACHMENT REGION BINDING PROTEIN; MUC2 PROTEIN, HUMAN; SATB2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; APPENDICEAL MUCINOUS NEOPLASM; APPENDIX TUMOR; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; OVARIAN MUCINOUS TUMOR; OVARY TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VOLUME; ADENOCARCINOMA, MUCINOUS; APPENDICEAL NEOPLASMS; COLORECTAL NEOPLASMS; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; APPENDICEAL NEOPLASMS; BIOMARKERS, TUMOR; CDX2 TRANSCRIPTION FACTOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; MATRIX ATTACHMENT REGION BINDING PROTEINS; MIDDLE AGED; MUCIN-2; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84957585835     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12899     Document Type: Article

References (32)

1. Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am. J. Surg. Pathol. 1991; 15; 415-429.
2. Ronnett BM, Shmookler BM, Diener-West M, Sugarbaker PH, Kurman RJ. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int. J. Gynecol. Pathol. 1997; 16; 1-9.
3. Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett BM. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am. J. Pathol. 1999; 154; 1849-1855.
4. Chuaqui RF, Zhuang Z, Emmert-Buck MR et al. Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Hum. Pathol. 1996; 27; 165-171.
5. Ronnett BM, Kurman RJ, Zahn CM et al. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum. Pathol. 1995; 26; 509-524.
6. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am. J. Surg. Pathol. 2000; 24; 1447-1464.
7. McKenney JK, Soslow RA, Longacre TA. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am. J. Surg. Pathol. 2008; 32; 645-655.
8. Vang R, Gown AM, Zhao C et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am. J. Surg. Pathol. 2007; 31; 854-869.
9. Stewart CJ, Tsukamoto T, Cooke B, Leung YC, Hammond IG. Ovarian mucinous tumour arising in mature cystic teratoma and associated with pseudomyxoma peritonei: report of two cases and comparison with ovarian involvement by low-grade appendiceal mucinous tumour. Pathology 2006; 38; 534-538.
10. Hwang JH, So KA, Modi G et al. Borderline-like mucinous tumor arising in mature cystic teratoma of the ovary associated with pseudomyxoma peritonei. Int. J. Gynecol. Pathol. 2009; 28; 376-380.
11. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am. J. Surg. Pathol. 2003; 27; 281-292.
12. Lewis MR, Deavers MT, Silva EG, Malpica A. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am. J. Surg. Pathol. 2006; 30; 177-184.
13. Guerrieri C, Franlund B, Fristedt S, Gillooley JF, Boeryd B. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. Hum. Pathol. 1997; 28; 1039-1045.
14. Vang R, Gown AM, Barry TS et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am. J. Surg. Pathol. 2006; 30; 1130-1139.
15. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int. J. Gynecol. Pathol. 2002; 21; 391-400.
16. Elias KM, Labidi-Galy SI, Vitonis AF et al. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecol. Oncol. 2014; 132; 328-333.
17. Shin JH, Bae JH, Lee A et al. CK7, CK20, CDX2 and MUC2 immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn. J. Clin. Oncol. 2010; 40; 208-213.
18. Stewart CJ, Ardakani NM, Doherty DA, Young RH. An evaluation of the morphologic features of low-grade mucinous neoplasms of the appendix metastatic in the ovary, and comparison with primary ovarian mucinous tumors. Int. J. Gynecol. Pathol. 2014; 33; 1-10.
19. Saad RS, Ghorab Z, Khalifa MA, Xu M. CDX2 as a marker for intestinal differentiation: its utility and limitations. World J. Gastrointest. Surg. 2011; 3; 159-166.
20. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am. J. Surg. Pathol. 2003; 27; 303-310.
21. Britanova O, Akopov S, Lukyanov S, Gruss P, Tarabykin V. Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS. Eur. J. Neurosci. 2005; 21; 658-668.
22. Magnusson K, de Wit M, Brennan DJ et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am. J. Surg. Pathol. 2011; 35; 937-948.
23. Dragomir A, de Wit M, Johansson C, Uhlen M, Ponten F. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am. J. Clin. Pathol. 2014; 141; 630-638.
24. Strickland S, Wasserman J, Giassi A, Parra-Herran C. Immunohistochemistry in the diagnosis of mucinous neoplasms involving the ovary: the added value of SATB2 and biomarker discovery through protein expression database mining. Int. J. Gynecol. Pathol. 2015; doi:10.1097/PGP.0000000000000238. Nov 3 [Epub ahead of print].
25. Perez Montiel D, Arispe Angulo K, Cantu-de Leon D, Bornstein Quevedo L, Chanona Vilchis J, Herrera Montalvo L. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic. Ann. Diagn. Pathol. 2015; 19; 249-252.
26. Bosman FT, Carneiro F, Hruban RH, Theise ND eds. World Health Organization classification of tumours. 4th ed. Lyon: IARC Press, 2010.
27. Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Siriaunkgul S. Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases. Int. J. Gynecol. Pathol. 2014; 33; 176-185.
28. Naik JD, Seligmann J, Perren TJ. Mucinous tumours of the ovary. J. Clin. Pathol. 2012; 65; 580-584.
29. Heatley MK. Mucinous tumours of the ovary-primary and metastatic. J. Clin. Pathol. 2012; 65; 577-579.
30. Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am. J. Surg. Pathol. 2008; 32; 128-138.
31. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am. J. Surg. Pathol. 2003; 27; 985-993.
32. Hu A, Li H, Zhang L et al. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality. J. Clin. Pathol. 2015; 68; 522-528.